Predicting continuous amyloid PET levels with CSF and plasma brain-derived p-tau217. | ScholarDeck

Paper

Predicting continuous amyloid PET levels with CSF and plasma brain-derived p-tau217.

New research · Nuclear Medicine

Alzheimer's & dementia : the journal of the Alzheimer's Association · 3w

Cohort studyAlzheimer's & dementia : the journal of the Alzheimer's Association· Aug 2026

Predicting continuous amyloid PET levels with CSF and plasma brain-derived p-tau217.

Lydia Trudel, Joseph Therriault, Arthur C Macedo … Alzheimer's Disease Neuroimaging Initiative

Read paper

Neurologic ImagingCohort studyDiagnosisQ1IF 11.9

Plasma brain-derived p-tau217 closely tracks continuous amyloid positron emission tomography burden.

Predicting continuous amyloid PET levels with CSF and plasma brain-derived p-tau217.

Lydia Trudel … Alzheimer's Disease Neuroimaging Initiative

Alzheimer's & dementia · Aug 2026

Background

Staging amyloid beta (Aβ) burden along a continuous spectrum provides clinically relevant information.

Methods

We tested how closely brain-derived p-tau217 reflected continuous Aβ and how accurately it could classify participants as Aβ positive or negative across different Centiloid (centiloid) thresholds in 924 participants from the Alzheimer's Disease Neuroimaging Initiative.

n = 924 participants

R2 = 0.63

Results

R2 = 0.63

brain-derived p-tau217 tracks amyloid burden closely, higher levels mean more amyloid

n = 924 participants

“

Conclusion

Plasma brain-derived p-tau217 best captured the amyloid positron emission tomography continuum, with brain-derived processing improving discrimination in plasma but not cerebrospinal fluid.

Read paper